Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Ellerson Group Inc. ADV’s 7th Largest Position

Ellerson Group Inc. ADV grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,920 shares of the biopharmaceutical company’s stock after acquiring an additional 59 shares during the quarter. Regeneron Pharmaceuticals accounts for 3.6% of Ellerson Group Inc. ADV’s holdings, making the stock its 7th largest holding. Ellerson Group Inc. ADV’s holdings in Regeneron Pharmaceuticals were worth $4,929,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Amundi boosted its stake in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after acquiring an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $127,489,000. KBC Group NV grew its holdings in shares of Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $65,180,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of REGN stock opened at $707.51 on Friday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a market capitalization of $77.35 billion, a P/E ratio of 18.48, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The business’s 50 day moving average is $696.12 and its two-hundred day moving average is $851.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on REGN shares. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. TD Cowen lowered their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Finally, UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.